Built on 20+ years of advancing critical care delivery, the PRISMAFLEX and PRISMAX Systems are designed to allow easy implementation of multiple modality options and therapies.

Nurse using the PRISMAFLEX System interface to administer CRRT to ICU Patient.

Continuous Renal Replacement Therapy

Designed with safety and ease of use in mind. PRISMAFLEX and PRISMAX Systems’ intuitive interface provides step-by-step user-guidance, and allows the flexibility to easily switch between four treatment modalities.

Additionally, the scale-based system provides accurate real-time measurement to help ensure a clear understanding of patient status and treatment parameters.

Therapeutic Plasma Exchange (TPE) 2000 Set on the PRISMAFLEX/PRISMAX System.

Therapeutic Plasma Exchange

Hospitals that own PRISMAFLEX or PRISMAX Systems can run membrane TPE without purchasing an additional machine. The disposable TPE 2000 Set is the only extra part needed to run this therapy on a PRISMAX or PRISMAFLEX System.

Molecular Adsorbent Recirculating System (MARS) machine can be used with the PRISMAFLEX System for drug overdose and poisoning therapy.

Liver Detoxification

MARS (Molecular Adsorbent Recirculating System) works with the PRISMAFLEX System* to provide support for the removal of harmful drugs and poisons in combination with CRRT. The MARS therapy is indicated for the treatment of drug overdose and poisoning. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.


*MARS currently available in the US for PRISMAFLEX System only.

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.